in extremely rare cases, life-threatening rhabdomyolysis. 7, 8 Drug-drug interactions (DDIs) that increase the serum concentration of statins can increase the risk of these muscle-related adverse events. 9 The aim of this article is to discuss the patient populations who are most at risk of statin DDIs, and outline dyslipidemia treatment choices that may reduce the risk of DDIs in these patients.
Molecular Basis of Statin Drug-Drug Interactions
In order to understand the molecular basis of statin DDIs, it is important to take into account the different pharmacokinetic properties that underlie their routes of metabolism and elimination (see Table 1 ). 9, 10 Statin DDIs are primarily caused by agents that inhibit their metabolism and transport. The metabolism of drugs generally occurs in two phases (see Figure 1 ). Phase I reactions involve introduction of a functional group to decrease their lipophilicity. This typically involves oxidation resulting in a variety of hydroxyl metabolites. If the drug is sufficiently hydrophilic, it will be eliminated from the body, if not, it will undergo Phase II reactions which involve conjugation with another hydrophilic molecule, further increasing their water solubility. Typical Phase II reactions include glucuronidation, acetylation, methylation, or formation of sulfate, glutathione or glycine conjugates. 11 Of the enzymes involved in Phase I reactions, the cytochrome P-450 (CYP) group is the most important. Within the CYP system, CYP3A4 is the most prevalent isoenzyme and metabolizes more than half of the drugs in current use. 12 Each of the common Phase I isoenzymes, CYP2C9, 2C19, 2D6 and 3A4/5 interact differently with the different statins because of their differing physiochemical properties. Lovastatin and simvastatin undergo extensive first-pass metabolism via CYP3A4, with atorvastatin being metabolized by CYP34A to a lesser extent. Fluvastatin is metabolized via CYP2C9, with CYP3A4 and CYP2C8 contributing to a lesser extent. 1 More recently developed statins such as rosuvastatin, and pitavastatin and older statins such as pravastatin, undergo minimal Phase I metabolism and their plasma concentrations are not significantly increased by CYP3A4 inhibitors. 13 This predominant role of CYP in the metabolism of many statins presents the potential for DDIs with CYP inhibitors, which can result in marked alterations in concentrations of drugs within this class. When lovastatin and simvastatin are used concurrently with a potent CYP3A4
inhibitor such as itraconazole, the statin serum concentration can be increased 10-to 20-fold. 14, 15 A retrospective database study found that patients who received statins with a concomitant CYP3A4 inhibitor had a six-fold increased rate of muscle-associated adverse reactions including rhabdomyolysis. 16 Atorvastatin is also metabolized by CYP3A4, but not as extensively as lovastatin and simvastatin. Accordingly, potent CYP3A4 inhibitors tend to produce two-to four-fold increases in atorvastatin serum concentrations. 17 The relationship between altered plasma Regular consumption of grapefruit juice (200 ml once daily) can increase simvastatin area under the curve (AUC) over three fold. 21 Therefore, grapefruit juice consumption is best avoided when taking a statin metabolized by CYP3A4. 22 Following reports of muscle-related side effects of statin therapy, particularly simvastatin, the FDA underwent their own surveillance and a review of the Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH) trial. 23 As a result, they have issued a number of safety announcements on potential DDIs, which have included discontinuation of the 80 mg dose of simvastatin and other dose restrictions when taken in combination with strong CYP inhibitors. [24] [25] [26] Lovastatin has also been given many dose restrictions by the FDA. 26 These are summarized in Table 2 .
Statin Drug Interactions in Patients with Comorbidities and on Multiple Medications
Of the statins that do not primarily depend on CYP3A4 for metabolic clearance, rosuvastatin is primarily eliminated as the unchanged parent compound but has but has some dependence on CYP2C9 and CYP2C19 for its metabolism. 27, 28 Pitavastatin is only minimally metabolized by CYP2C9 and to a lesser extent CYP2C8 and is mainly metabolized by glucuronidation. As a result, it does not interact with CYP3A4 inhibitors, increasing the drug's tolerability profile. 9, 29 A large post-marketing study conducted in more than 20,000 patients in Japan 30 found that the rate of adverse drug reactions with pitavastatin treatment was 6.1 %, around half that observed with atorvastatin and rosuvastatin (12.0 and 11.1 % respectively). 9 These included increases in blood creatine phosphokinase, alanine aminotransferase, aspartate aminotransferase gamma-glutamyltransferase, and also myalgia.
One pharmacokinetic property shared by all statins is extensive first pass hepatic extraction. Access into the liver is an important step prior to metabolism and elimination of the statins. This is accomplished by two primary mechanisms-active transport and passive diffusion (see Figure 2 ). Organic anion transporting polypeptides (OATPs) form a family of membrane influx transporter proteins that actively transport all statins to some extent. 31 Hydrophilic statins such as pravastatin and rosuvastatin are transported from the portal circulation into the hepatocyte 32 by
OATPs. OATP1B1 also appears to have a selective role in pitavastatin transport 33 Atorvastatin, fluvastatin, lovastatin, and simvastatin enter hepatocytes mainly by passive diffusion; however, the acid forms of these statins also utilize active transport mechanisms. 34, 35 Inhibition of hepatic uptake transporters and reduced transport activity have the potential to cause significant DDIs. 34 Cyclosporine inhibits several influx and efflux transporters, including OATP1B3, OATP2B1, as well as CYP3A4 36 and has been shown to increase plasma concentrations of lovastatin. 37 However cyclosporine has been shown to increase plasma concentrations of statins that are not significantly metabolized by CYP3A4;
interactions between cyclosporine and rosuvastatin, 38 and pitavastatin The membrane protein P-glycoprotein (P-gp), 13 an efflux protein located in the gastrointestinal tract, placenta, kidneys, brain, and liver, is believed to affect the bioavailability and elimination of statins, primarily in the acid form, and may therefore play a role in DDIs. [41] [42] [43] Studies of in vitro models have found that atorvastatin, simvastatin, and lovastatin are substrates for P-gp while pravastatin, fluvastatin and the acid form of pitavastatin do not show significant inhibition of P-gp. 41, [44] [45] [46] Data from drug interaction studies involving statins and digoxin have suggested the involvement of P-gp. 47 Many drugs known to cause DDIs with statins are modulators of P-gp, and include diltiazem, verapamil, itraconazole, ketoconazole, and cyclosporine, as well as St John's wort and grapefruit juice. However, the role of P-gp in these specific DDIs is unclear. 41 Multidrug resistance associated proteins (MDR1 and MDP2) and breast cancer resistance protein (BRCP) may also be involved in the efflux of statins.
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Impact of Drug-Drug Interactions on Statin Usage
Many patients receiving statins are elderly, and/or have comorbid conditions such as diabetes, hypertension, and CHD. Treatment of patients at high risk for CVD invariably involves the prescription of multiple medications. As the clinical complexity of patients increases, so does the potential for DDIs. A high proportion of patients are co-prescribed a statin with potentially interacting drugs, and therefore the impact of polypharmacy on the safety profile of statins may be not be fully recognized. 48 It is also important to remember that polypharmacy involves not only prescribed medications but also over-the-counter medications, including vitamins, minerals, herbal remedies and foodstuffs such as grapefruit juice and fresh grapefruit.
A recent study examined the concomitant exposure of patients to CYP3A4-metabolized statins and CYP3A4 inhibitors in the UK primary care population. In this analysis, which included a total of 364,574 patients, the majority (93 %) of the patients were prescribed
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CYP3A4-metabolized statins, most of whom received simvastatin (72 %)
and atorvastatin (24 %). Almost one third of (30 %) of patients prescribed a CYP3A4-metabolized statin were also prescribed a CYP3A4 inhibitor (predominantly macrolide antibiotics, or calcium channel blockers). 49 Many commonly used drugs are moderate-to-potent inhibitors of CYP3A4. These include calcium channel blockers, antifungals, antidepressants, antiretrovirals, immunosuppressants, and macrolide antibiotics. 50 Statin plasma levels may also be decreased as a result of DDIs; this has been reported in CYP inducers such as rifampicin 51 phenytoin 52 and St John's wort. 53 A summary of clinically significant statin DDIs is given in Table 3 .
The Understanding statin use in America and gaps in education (USAGE) survey assessed the attitudes, beliefs and behavior of current and former statin users. 54 Nearly half of the 10,138 patients surveyed had switched or discontinued statin use, and amongst former statin users, 65 % cited side effects as the primary reason for discontinuation (see Figure 3) . Muscle-related side effects were reported by 60 % and 25 % of former and current users, respectively. The average respondent used three prescription and/or non-prescription products with the potential to cause DDIs. Of the respondents, 84 % used at least one product with known DDI potential. Despite this, only 38 % of all respondents reported concern with potential DDIs.
The survey revealed important communication gaps regarding DDIs. Only 26 % of respondents spoke to their doctor about the possibility of DDIs.
Of the respondents, 42 % who had concerns about DDIs but did not discuss them with their doctor stated that they relied on their pharmacist to identify potential DDIs. In fact, 57 % believed that the pharmacist was responsible for managing this issue, although a pharmacist may not be aware of their complete treatment regimen since patients may use more than one pharmacy. These findings highlight the need for discussion and education about DDIs within the clinical consultation.
Patient Populations at Risk of Drug-Drug Interactions
Certain subgroups of patients have an increased risk for DDIs compared to the general population, and include the elderly and those with comorbidities such as CVD and HIV. 56 In a recent study of concomitant exposure of patients to CYP3A4-metabolized statins and CYP3A4
Drug-Drug Interactions Risk in the Elderly
inhibitors in the UK primary care population, DDI rates were highest in the subgroup aged 65 and over. 49 Clinical evidence supports the use of statins in elderly patients despite the elevated risk of DDIs. 57 Two recent studies found that pitavastatin and pravastatin are safe and effective in elderly patients with primary hypercholesterolemia or combined dyslipidemia. In one (n=641), pitavastatin showed significantly greater lipid-lowering efficacy over 12 weeks. 58 The other (n=539) was a long term extension to 60 weeks but without an active comparator.
Pitavastatin demonstrated long-term safety and efficacy in this patient population. 59 
Drug-Drug Interactions Risk in Patients with Cardiovascular Disease
Statin DDIs may occur with cardiovascular agents such as calcium channel blockers, antiarrhythmics, digoxin and warfarin (see Table 2 ).
Calcium-channel blockers are frequently co-prescribed with statins since hypertension and chronic stable angina are a common comorbidity in patients with dyslipidemia. However, certain calcium channel blockers such as verapamil and diltiazem are weak or moderately potent CYP3A4 inhibitors 13 and have been shown to significantly increase serum concentrations of both lovastatin and simvastatin. [60] [61] [62] The FDA has introduced dose limitations on verapamil and diltiazem for these two statins. 24 Other statins, such as pitavastatin, have not been shown to significantly interact with calcium channel blockers. In a pharmacokinetics study in healthy volunteers, pitavastatin total (AUC) and peak (Cmax) exposure was only minimally increased by 10 % and 15 %, respectively.
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The anti-arrhythmic agent amiodarone is also a potent CYP34A inhibitor.
A study of concomitant amiodarone therapy in statin-associated AEs, concluded that although the incidence is relatively rare, clinicians
should be vigilant about muscle-related complaints in elderly patients on multiple medications who are being treated with a statin and amiodarone. 64 The dosage of simvastatin is limited when used in combination with amiodarone based on an FDA announcement. 25 The angina therapy ranozaline has also been found to increase plasma concentrations of simvastatin twofold. 65 Cardiovascular Risk 75, 76 and inhibition of CYP2C8 and OATP1B1. 13 In contrast, fenofibrate has a minimal effect on the metabolic pathways of statins although it is a CYP2C9 inhibitor. Protease inhibitors are potent inhibitors of CYP3A4. 83 The simvastatin AUC increases 32-fold when co-administered with the combination of saquinavir/ritonavir, white atorvastatin increases approximately twofold. 83 Pravastatin can be used safely with most protease inhibitors 83 although it may be less effective as a result of induction of enzymes that metabolize pravastatin. 84 When administered with darunavir, however, pravastatin levels may increase up to fivefold 83 depending on polymorphisms within the SLCO1B1 drug transporter gene thereby making it difficult to predict whether a significant interaction will occur or not. 85 The 
Summary and Concluding Remarks
The 
